Molecular Partners AG MOLN.SW Stock
Molecular Partners AG Price Chart
Molecular Partners AG MOLN.SW Financial and Trading Overview
| Molecular Partners AG stock price | 3.54 CHF |
| Previous Close | 6 CHF |
| Open | 5.98 CHF |
| Bid | 5.91 CHF x 0 |
| Ask | 6.05 CHF x 0 |
| Day's Range | 5.98 - 6.1 CHF |
| 52 Week Range | 5.22 - 7.63 CHF |
| Volume | 2.09K CHF |
| Avg. Volume | 18.64K CHF |
| Market Cap | 221.82M CHF |
| Beta (5Y Monthly) | 0.622988 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.89 CHF |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.5 CHF |
MOLN.SW Valuation Measures
| Enterprise Value | -33781780 CHF |
| Trailing P/E | N/A |
| Forward P/E | -4.06 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 11.1652355 |
| Price/Book (mrq) | 0.8924385 |
| Enterprise Value/Revenue | -1.7 |
| Enterprise Value/EBITDA | 0.674 |
Trading Information
Molecular Partners AG Stock Price History
| Beta (5Y Monthly) | 0.622988 |
| 52-Week Change | -8.95% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 7.63 CHF |
| 52 Week Low | 5.22 CHF |
| 50-Day Moving Average | 5.84 CHF |
| 200-Day Moving Average | 6.05 CHF |
MOLN.SW Share Statistics
| Avg. Volume (3 month) | 18.64K CHF |
| Avg. Daily Volume (10-Days) | 16.99K CHF |
| Shares Outstanding | 36.06M |
| Float | 14.42M |
| Short Ratio | N/A |
| % Held by Insiders | 19.83% |
| % Held by Institutions | 43.70% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -251.93% |
| Operating Margin (ttm) | -256.85% |
| Gross Margin | -146.49% |
| EBITDA Margin | -252.44% |
Management Effectiveness
| Return on Assets (ttm) | -11.46% |
| Return on Equity (ttm) | -20.57% |
Income Statement
| Revenue (ttm) | 19.87M CHF |
| Revenue Per Share (ttm) | 0.61 CHF |
| Quarterly Revenue Growth (yoy) | -98.20% |
| Gross Profit (ttm) | 138.85M CHF |
| EBITDA | -50153000 CHF |
| Net Income Avi to Common (ttm) | -50052000 CHF |
| Diluted EPS (ttm) | -1.5 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 232.37M CHF |
| Total Cash Per Share (mrq) | 7.14 CHF |
| Total Debt (mrq) | 4.55M CHF |
| Total Debt/Equity (mrq) | 2.05 CHF |
| Current Ratio (mrq) | 15.443 |
| Book Value Per Share (mrq) | 6.824 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -61540000 CHF |
| Levered Free Cash Flow (ttm) | -38268500 CHF |
Profile of Molecular Partners AG
| Country | Switzerland |
| State | N/A |
| City | Schlieren |
| Address | Wagistrasse 14 |
| ZIP | 8952 |
| Phone | 41 44 755 77 00 |
| Website | https://www.molecularpartners.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 175 |
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops ankyrin proteins for the treatment of oncology and virology diseases. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration, as well as for diabetic macular edema; and ensovibep (MP0420), a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, a DARPin molecule, which activates T-cells and other immune cells; MP0317, that allows tumor-restricted immune-cell CD40 activation for the treatment of fibroblast activation protein (FAP) positive cancers, which is in Phase I clinical trials; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274, that uses HER2-specific DARPin binding proteins. It also develops MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor (VEGF)and hepatocyte growth factor. Molecular Partners AG has license and research collaboration agreements with Novartis AG to develop DARPin-conjugated radioligand therapies, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Q&A For Molecular Partners AG Stock
What is a current MOLN.SW stock price?
Molecular Partners AG MOLN.SW stock price today per share is 3.54 CHF.
How to purchase Molecular Partners AG stock?
You can buy MOLN.SW shares on the Swiss exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Molecular Partners AG?
The stock symbol or ticker of Molecular Partners AG is MOLN.SW.
Which industry does the Molecular Partners AG company belong to?
The Molecular Partners AG industry is Biotechnology.
How many shares does Molecular Partners AG have in circulation?
The max supply of Molecular Partners AG shares is 32.87M.
What is Molecular Partners AG Price to Earnings Ratio (PE Ratio)?
Molecular Partners AG PE Ratio is now.
What was Molecular Partners AG earnings per share over the trailing 12 months (TTM)?
Molecular Partners AG EPS is -1.89 CHF over the trailing 12 months.
Which sector does the Molecular Partners AG company belong to?
The Molecular Partners AG sector is Healthcare.
Molecular Partners AG MOLN.SW included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Developed ex US SC NTR G NQDMXUSSCGBPN | 1704.47 GBP 2179.91 USD |
0
|
— — | 1704.47 GBP 2179.91 USD | 1704.47 GBP 2179.91 USD | — - | — — |
| SPI TR SSHI | 15051.28 CHF 17125.13 USD |
-0.5
|
— — | 15030.9 CHF 17101.95 USD | 15256.93 CHF 17359.12 USD | — - | — — |
- {{ link.label }} {{link}}